GlassScriptPhysician profile
Abby Lee Lauer
NPI 1902339294
$4,406.79
in general payments reported to CMS, 2019-2025
23 companies · $781 in 2025
The $781 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $300 · 2023: $1,753 · 2024: $1,573 · 2025: $781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,106.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,080.29 | 2023-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $924.17 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $507.54 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $417.97 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Axsome Therapeutics, INC. | $299.21 | 2023-2025 | Auvelity |
| Pfizer INC. | $208.20 | 2022-2025 | |
| Amgen INC. | $157.57 | 2022-2025 | Repatha, Otezla, Evenity |
| Exact Sciences Corporation | $157.12 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $115.86 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.18 | 2022-2025 | Jardiance, Tradjenta |
| Astellas Pharma US INC | $86.73 | 2024-2025 | Veozah |
| Almatica Pharma LLC | $51.55 | 2022 | |
| Idorsia Pharmaceuticals US INC | $49.01 | 2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $48.63 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $30.71 | 2022-2024 | Austedo Xr |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $30.43 | 2023-2024 | Gardasil 9, Capvaxive, Gardasil |
| Gilead Sciences, INC. | $26.02 | 2024 | |
| Lucid Diagnostics INC. | $23.10 | 2024 | |
| Sanofi Pasteur INC. | $22.95 | 2023 | |
| Esperion Therapeutics, INC. | $21.33 | 2023 | Nexletol |
| Supernus Pharmaceuticals, INC. | $19.98 | 2024 | Qelbree |
| Kowa Pharmaceuticals America, INC. | $16.16 | 2022 | |
| Abbott Laboratories | $16.08 | 2025 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abby Lauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.